Vaborbactam_DataSheet_MedChemExpress

格式：pdf
大小：114.72 KB
文档页数：1

下载文档原格式

安进—阿法达贝泊汀 PPT课件

阿法达贝泊汀被认可史
2001年首次获得欧盟批准，用于治疗11岁及以上儿童至成人的慢性肾病相关贫血。 2002年，获准治疗正接受化疗之成人实体瘤患者贫血。 2003年，此适应证的适用对象获准扩展至正接受化疗之成人非骨髓性恶性肿瘤癌症人群的有症状贫血治疗。

2004年，获准可以每3周1次给药频率治疗正接受化疗之成人非骨髓性恶性肿瘤癌症患者贫血及能以每月1次剂量间隔方案治疗尚未进行透析之慢性肾病人群贫血。 2006年，阿法达贝泊汀再被更新至允许正进行透析之慢性肾病个体自每周1～3次给药重组人DNA促红细胞生成素类药物切换到每2周1次给药阿法达贝泊汀疗法。 2007年，欧盟委员会已批准扩展其适用对象至所有已在或尚未接受透析治疗之儿科慢性肾病或称慢性肾衰相关贫血个体治疗。
一药物基本信息

英文药名: Aranesp 中文药名: 阿法达贝泊汀注射剂通用名：darbepoetin alfa 其他名：Aranesp; NESP, Amgen; NESP, Kirin;Novel Erythropoiesis Stimulati; 生产厂家: 安进公司作用：治疗贫血
安进产品涉及领域

作为全球最大生物制药企业的“安进公司” （Amgen）,虽贵为全球生物医药产业领头羊，拥有极强的研发能力和产品优势，坚持在疾病治疗的生物技术领域内发展，主要涉足的领域有人类基因组，癌症，神经科学和小分子化学等.
发展历程
1988年，公司规模还很小，员工仅479人，没有任何产品上市。1989年6月安进公司的第一个产品重组人红细胞生成素(简称EPO) 获得美国FDA批准，用于治疗慢性肾功能衰竭引起的贫血和HIV感染治疗的贫血． 1991年2月公司第二个产品重组粒细胞集落刺激因子(G-CSF)获得美国FDA批准，其适应证为肿瘤化疗引起的嗜中性白细胞减少症。安进公司的这两个全球商业化最为成功的生物技术药物EPO和G-CSF，为公司带来了巨额的利润，公司也据此迅速发展壮大。

分子生物学词汇(中英文对照表 )

2022最新帕拉米韦杂质列表汇总(现)

帕拉米韦相关杂质整理列表（现）
货号名称
结构式
分子式
CAS
号
备注
P023013 帕拉米韦杂质 13 C15H28N4O4
T：18576690-
176
提供COA
氢谱
质谱
液相
P023029 帕拉米韦杂质29
C15H28N4O4
N/A
提供COA
氢谱
质谱
液相
P023030 帕拉米韦杂质30 C14H28N6O3 N/A
提供COA
氢谱
质谱
液相
P023033 帕拉米韦杂质33
C12H24N2O3
N/A
提供COA
氢谱
质谱
液相
P023046 帕拉米韦双乙酰杂质C17H30N4O5 N/A
提供COA
氢谱
质谱
液相
P023048
帕拉米韦脱水脱乙酰杂质
C13H24N4O2
Q：2851922763
提供COA
氢谱
质谱
液相
更多帕拉米韦杂质详情（深圳恒丰万达医药科技）
纯度：>95%
用途：供新药研究及实验使用
规格：10mg/25mg/50mg/100mg
更多优势项目杂质：
硼替佐米，卡比多巴，克拉霉素，克林霉素，达非那新，地塞米松，依那普利，恩氟沙星，法莫替丁，依托必利，兰索拉唑，左氧氟沙星，氯雷他定，利多卡因，拉西地平，甲氨蝶呤，莫西沙星，诺氟沙星，尼美舒利，奥美拉唑，奥司他韦，氧氟沙星，泮托拉唑，帕罗西汀，雷贝拉唑，利托那韦，卡巴拉汀，瑞舒伐他汀，雷尼替丁，罗红霉素，沙丁胺醇，西他列汀，舍曲林，索菲那新，舒马曲坦，辛伐他汀，西洛多辛，托莫西汀，氨甲环酸，替卡格雷，替卡西林，替米沙坦，伐地那非等。

布地奈德与复方异丙托溴铵雾化吸入

DOI：10.19368/ki.2096-1782.2022.19.155布地奈德与复方异丙托溴铵雾化吸入用于小儿哮喘治疗中的临床研究陈炜，马泽南，邹公民苏州市吴中人民医院儿科，江苏苏州215000[摘要]目的探讨对小儿哮喘采用布地奈德联合复方异丙托溴胺雾化吸入的临床效果。

方法选择苏州市吴中人民医院2018年1月—2021年12月收治的小儿哮喘者80例，以随机数表法分为对照组（n=40，布地奈德联合沙丁胺醇治疗）与观察组（n=40，布地奈德联合复方异丙托溴铵治疗），比较两组临床疗效，典型症状改善时间与住院时间，并检测治疗前后第一秒用力呼气量（FEV1）、FEV1/用力肺活量（FVC）、呼气峰值流速（PEF）评估患儿肺功能，统计不良反应情况评估用药安全性。

结果观察组总有效率较对照组高（97.50% vs 80.00%），差异有统计学意义（χ2=4.507，P<0.05）。

治疗后，观察组咳痰咳嗽、肺哮鸣音、呼吸困难、肺啰音改善时间与住院时间分别为（4.51±1.74）、（3.59±1.36）、（2.75±1.27）、（2.65±1.15）、（4.60±1.52）d，均短于对照组，差异有统计学意义（t=3.789、5.404、6.664、7.356、4.623，P<0.05）。

观察组FEV1、FEV1/FVC、PEF水平分别为（1.72±0.16）L、（82.12±7.80）%、（4.20±0.58）L/s，均高于对照组，差异有统计学意义（t=6.633、3.891、5.811，P< 0.05）。

两组不良反应发生率（5.00% vs 10.00%）差异无统计学意义（χ2=0.180，P>0.05）。

结论对小儿哮喘予以布地奈德联合复方异丙溴铵进行雾化吸入可提升治疗效果，能加快哮喘症状的缓解，且可提高肺功能。

工作场所空气中有毒物质容许浓度

3 2 -15* 40* 50* 0.9* 2 450* -0.6* 1 25*
34 35 36 37 38
39 40 41 42 43 44 45 46 47 48
碲化铋（按 Bi2Te3 计）（1304-82-1）碘（7553-56-2）碘仿（75-47-8）碘甲烷（皮）（ 74-884）叠氮酸和叠氮化钠（ 7782-79-8 ； 2662822-8 ）叠氮酸蒸气叠氮化钠丁醇（71-36-3） 1,3-丁二烯(106-99-0) 丁醛（123-72-8）丁酮（78-93-3）丁烯（25167-67-3）对苯二甲酸（ 100-210）对硫磷（皮）（ 56-382）对特丁基甲苯（ 98-511）对硝基苯胺（皮）（100-01-6）对硝基氯苯/二硝基氯苯（皮）（ 100-005/25567-67-3）多次甲基多苯基多异氰酸酯（57029-46-6）二苯胺（122-39-4）二苯基甲烷二异氰酸酯（101-68-8）二丙二醇甲醚（皮) （34590-94-8） 2-N- 二丁氨基乙醇（皮）（102-81-8）二恶烷（皮）（123-911）二氟氯甲烷（75-45-6）二甲胺（124-40-3）二甲苯（全部异构体）（ 1330-20-7 ； 95-476；108-38-3）二甲苯胺（皮）（ 12169-7） 1,3- 二甲基丁基醋酸酯（仲 - 乙酸己酯） (10884-9)
Bismuth telluride ， as Bi2Te3 Iodine Iodoform Methyl iodide(skin) Hydrazoic acid and sodium azide Hydrazoic acid vaporsodium azide Butyl alcohol 1,3-Butadiene Butyladehyde Methyl ethyl ketone Butylene Terephthalic acid Parathion(skin) p-Tert-butyltoluene p-Nitroaniline(skin) pNitrochlorobenzene/Din itrochlorobenzene(skin ) Polymetyhlene polyphenylisocyanate(P MPPI) Diphenylamine Diphenylmethane diisocyanate Dipropylene glycolmethyl ether(skin) 2-NDibutylaminoethanol(sk in) 1,1,4-Dioxane(skin)

Presatovir产品说明书

1. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Presatovir Catalog No. :HY-16727CAS No. :1353625-73-61.2 Relevant identified uses of the substance or mixture and uses advised against Identified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USA Tel:609-228-6898Fax:609-228-5909E-mail:1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:GS-5806Formula:C 24H 30ClN 7O 3S Molecular Weight:532.06CAS No. :1353625-73-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician. Skin contactSafety Data SheetRevision Date:Jun.-3-2021Print Date:Feb.-17-2023Inhibitors •Screening Libraries•ProteinsRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance SolidOdor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 2Additional informationThis information is based on our current knowledge. However the chemical, physical, and toxicological properties have not been completely investigated.12. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)Proper shipping name: Not dangerous goodsUN number: -Class: -Packing group: -IMDGProper shipping name: Not dangerous goodsUN number: -Class: -Packing group: -IATAProper shipping name: Not dangerous goodsUN number: -Class: -Packing group: -15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2023 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel:609-228-6898Fax:609-228-5909E-mail:***********************Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

玛巴洛沙韦结构式

玛巴洛沙韦结构式全文共四篇示例，供读者参考第一篇示例：玛巴洛沙韦（Mavlabosavir，又称Pimodivir）是一种广谱的抗流感病毒药物，属于口服的新型RNA干扰剂。

其化学结构式为C23H26FN7O2，分子量为449.499 g/mol。

玛巴洛沙韦如今已被证实对包括甲型和乙型流感病毒在内的多种流感病毒具有很强的抑制作用。

它采用一种独特的机制来阻断病毒的生长和复制，从而有效地减轻病毒感染的症状。

玛巴洛沙韦的化学结构体现了其抗流感病毒的作用机制。

该药物是一种强效的非核苷类反转录酶抑制剂，通过干扰流感病毒的RNA复制而达到抑制病毒生长的效果。

其结构中包含有一个异氮杂环和多个氟原子，这些特殊的结构单元赋予了玛巴洛沙韦出色的抗病毒活性。

从结构上看，玛巴洛沙韦的核心结构是一个含氮杂环的环戊烯酮（cyclopentenone），在环戊烯的位置上连接有一个含氟的芳香族环。

这种结构形式为玛巴洛沙韦提供了非常强的疏水性，使其能够在病毒颗粒内部精准地与反转录酶结合，进而阻断病毒的复制与传播。

在化学结构中还包含有一个异噻唑环和多个取代基。

异噻唑环是一种含硫杂环结构，能够增强分子的稳定性和生物活性。

这些取代基对分子的生物活性及亲合力也起到了关键的作用，通过特定的相互作用与病毒RNA或蛋白结合，最终实现抗病毒作用。

玛巴洛沙韦的化学结构具有独特的设计，使其在与流感病毒的特定靶标相互作用时能够表现出卓越的活性。

通过对病毒复制过程的干扰，玛巴洛沙韦有效地抑制了病毒的生长，为治疗流感提供了一种新的选择。

随着对其药效和安全性的进一步研究，玛巴洛沙韦有望成为未来治疗流感的重要药物之一。

【参考资料来源于维基百科等网站】。

第二篇示例：玛巴洛沙韦（Mavrolashavi）是一种抗病毒药物，广泛用于治疗各种病毒性疾病。

它主要用于治疗艾滋病毒感染和流感等病毒感染。

玛巴洛沙韦的结构式为C44H46F2N6O8，化学式为C44H46F2N6O8，分子量为810.871。

感控相关英语单词短语及缩写中英对照

中文
抗生素相关腹泻鲍曼不动杆菌免疫实践咨询委员会主动筛查腺病毒主动检测和隔离全自动内镜清洗消毒机产生气溶胶的操作抗酸杆菌美国医院协会速干手消毒剂经空气传播疾病急性白血病氨基青霉素耐药性抗菌缝线抗菌药物管理团队抗菌剂美国感染控制与流行病学专业协会成人型呼吸窘迫综合征耐药性微生物耐药性病原体抗菌药物管理项目黑曲霉菌抗菌药物敏感性试验抗菌药物应用和耐药性苯扎氯铵菌血症细菌性气溶胶细菌性腹膜炎血源性病原体床旁隔离生物膜血琼脂平板呼吸回路布里斯托分型表广谱抗生素布鲁氏菌血流感染
临时性血管通路终末消毒清洗效果测试物四环素替加环素全髋关节置换术全肠外营养阿萨希毛孢子菌甲氧苄氨嘧啶万古霉素呼吸机相关肺炎汽化过氧化氢霍乱弧菌创伤弧菌耐万古霉素肠球菌耐万古霉素屎肠球菌水痘-带状疱疹病毒白细胞计数西尼罗病毒泛耐药鲍曼不动杆菌泛耐药
感控相关英语单词、短语及缩写
Buffer room Burkholderia cepacia CA－BSI (catheter-associated blood stream infections) Campylobacter jejuni CA-MRSA （community associated MRSA ） Candida parapsilosis Carbapenems CASS（continuous aspiration of subglottic secretions） Candida albicans CAUTI(Catherter—associated urinary tract infection) CBIC（Certification Board of Infection Control and Epidemiology） CCNA（cell cytotoxin neutralization assay） CCT（ Controlled clinical trail ） CDAD (Clostridium difficile–associated disease) CDI（Clostridium difficile infection） Cephalosporins CHA(Chlorhexidine acetate) CHG(Chlorhexidine gluconate) Chlamydia trachomatis Chlorine product CJD（Creutzfedt-Jekob disease） CLABSI(central line-associated bloodstream infections) CLAD（closed Luer access device） Clindamycin Clostridium perfringens Colistin colonisation CoNS(coagulase-negative staphylococci) Contact isolation CoV（coronavirus） CoxA16(Coxsackievirus) CPE（carbapenemase-producing Enterobacteriaceae） CPIS(clinical pulmonary infection score) CPS(coagulase-positive staphylococci) CRAB(Carbapenem-resistant Acinetobacter) CRE(carbapenem-resistant Enterobacteriaceae) Critical dental instruments CRKP（carbapenem-resistant Klebsiella pneumoniae） CRV（community respiratory viruses） CSSD（Central sterile supply department） Decontamination area Dental scaler Di间洋葱伯克霍尔德菌导管相关血流感染空肠弯曲杆菌社区相关甲氧西林耐药金葡菌近平滑假丝酵母菌碳青霉烯类持续声门下吸引白色念珠菌导尿管相关尿路感染感染控制与流行病学认证委员会细胞毒素中和试验临床对照试验艰难梭菌相关性腹泻艰难梭菌感染头孢菌素类醋酸氯已定葡萄糖酸氯已定沙眼衣原体含氯消毒剂克雅病中心静脉导管相关血流感染密封的鲁尔接着装置克林霉素产气荚膜梭菌黏菌素定植凝固酶阴性葡萄球菌接触隔离冠状病毒柯萨奇A16型病毒产碳青霉烯酶肠杆菌临床肺部感染评分凝固酶阳性葡萄球菌耐碳青霉烯鲍曼不动杆菌耐碳青霉烯类肠杆菌高危口腔器械耐碳青霉烯肺炎克雷伯菌社区呼吸道病毒消毒供应中心去污区牙洁治器透析

爱利亚（阿培布塞普）商品说明书

Eylea® (aflibercept)Document Number: IC-0026 Last Review Date: 04/26/2016Date of Origin: 02/07/2013Dates Reviewed: 03/07/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015,4/2015, 6/2015, 9/2015, 3/2016, 4/2016I.Length of AuthorizationCoverage will be provided for six months and may be renewed.II.Dosing LimitsA.Quantity Limit (max daily dose) [Pharmacy Benefit]:− 2 mg injection - 1 vial every 28 daysB.Max Units (per dose and over time) [Medical Benefit]:AMD:Loading dose:Male 2 units every 28 days per eye x 3 doses*Female 2 units every 28 days per eye x 3 doses*Maintenance:Male 2 units every 56 days per eye*Female 2 units every 56 days per eye*Macular Edema following RVOMale 2 units every 28 days per eye*Female 2 units every 28 days per eye*Diabetic Macular EdemaLoading dose:Male 2 units every 28 days per eye x 5 doses*Female 2 units every 28 days per eye x 5 doses*Maintenance:Male 2 units every 56 days per eye*Female 2 units every 56 days per eye**Max units are doubled (4 billable units) when the claim is submitted with bilateral ICD 10 codesIII.Initial Approval CriteriaCoverage is provided in the following conditions:•Patient is free of ocular and/or peri-ocular infections: AND•Baseline visual acuity test (required for renewal); AND one of the following:o Neovascular age-related macular degeneration (AMD) †o Macular edema following retinal vein occlusion (RVO) †o Diabetic Macular Edema (DME) †o Diabetic retinopathy (DR) associated with diabetic macular edema (DME) † † FDA Approved Indication(s)IV.Renewal CriteriaCoverage can be renewed based upon the following criteria:•Patient continues to meet criteria identified in section III; AND•Disease response as indicated by stabilization of visual acuity or improvement in BCVA score when compared to baseline; AND•Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: Endophthalmitis and retinal detachments; increase in intraocularpressure; arterial thromboembolic events.V.Dosage/AdministrationVI.Billing Code/Availability InformationJcode:J0178– Eylea (Regeneron) 2 mg Injection: 1 billable unit = 1 mgNDC:Eylea 2 mg Injection – 61755-0005-xx (Regeneron)VII.References1.Eylea [package insert]. Tarrytown, NY; Regeneron Pharmaceuticals, Inc.; July 2015.Accessed February 2016.2.Wisconsin Physicians Service Insurance Corporation. Local Coverage Determination (LCD):Drugs and Biologics (Non-chemotherapy) (L4741). Centers for Medicare & MedicaidServices, Inc. Updated on 01/01/2016 with effective date 01/01/2016. Accessed February2016.3.National Government Services, Inc. Local Coverage Article for Ranibizumab (e.g.,Lucentis™) and Aflibercept (e.g., Eylea™) – Related to LCD L33394 (A52451). Centers forMedicare & Medicaid Services, Inc. Updated on 09/13/2015 with effective date of10/01/2015. Accessed February 2016.Appendix 1 – Covered Diagnosis Codes (*Max Units for bilateral indications are doubled)E08.311 Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edemaE08.321 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edemaE08.331 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edemaE08.341 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edemaE08.351 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edemaE09.311 Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edemaE09.321 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edemaE09.331 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edemaE09.341 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edemaE09.351 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edemaE10.311 Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edemaE10.321 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E10.331 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edemaE10.341 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema E10.351 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edemaE11.311 Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edemaE11.321 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E11.331 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edemaE11.341 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema E11.351 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edemaE13.311 Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edemaE13.321 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edemaE13.331 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edemaE13.341 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edemaE13.351 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edemaH34.811 Central retinal vein occlusion, right eyeH34.812 Central retinal vein occlusion, left eyeH34.813 Central retinal vein occlusion, bilateral*H34.819 Central retinal vein occlusion, unspecified eyeH34.831 Tributary (branch) retinal vein occlusion, right eyeH34.832 Tributary (branch) retinal vein occlusion, left eyeH34.833 Tributary (branch) retinal vein occlusion, bilateral*H34.839 Tributary (branch) retinal vein occlusion, unspecified eyeH35.32 Exudative age-related macular degenerationH35.81 Retinal edemaAppendix 2 – Centers for Medicare and Medicaid Services (CMS)Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: /medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):Jurisdiction(s): 5, 8NCD/LCD Document (s): L34741https:///medicare-coverage-database/details/lcd-details.aspx?LCDId=34741&ver=22&Date=02%2f02%2f2016&DocID=L34741&bc=iAAAAAgAA AAAAA%3d%3d&Jurisdiction(s): 6, J-K NCD/LCD Document (s): A52451https:///medicare-coverage-database/details/article-details.aspx?articleId=52451&ver=9&Date=02%2f02%2f2016&DocID=A52451&SearchType=Ad vanced&bc=JAAAAAgAAAAAAA%3d%3d&Jurisdiction Applicable State/US Territory ContractorE CA,HI, NV, AS, GU, CNMI Noridian Administrative Services (NAS)Noridian Administrative Services (NAS)F AK, WA, OR, ID, ND, SD, MT, WY,UT, AZ5 KS, NE, IA, MO Wisconsin Physicians Service (WPS)6 MN, WI, IL National Government Services (NGS)H LA, AR, MS, TX, OK, CO, NM Novitas Solutions8 MI, IN Wisconsin Physicians Service (WPS)9 (N) FL, PR, VI First Coast Service Options10 (J) TN, GA, AL Cahaba Government Benefit Administrators11 (M) NC, SC, VA, WV Palmetto GBA12 (L) DE, MD, PA, NJ, DC Novitas SolutionsK NY, CT, MA, RI, VT, ME, NH National Government Services (NGS)15 KY, OH CGS Administrators, LLC。

Vabomere药品说明书

.106.World Notes on Antibiotics, 2019, Vol.40, No.2Vabomere 药品说明书黄志伟编译，张菁**校审（复旦大学附属华山医院抗生素研究所，上海20040）收稿日期：2018-12-15基金项目：科技部“重大新药创制”科技重大专项资助（2017ZX09304005）。

作者简介：黄志伟，研究生，主要研究方向为药物I 期临床试验。

*通信作者：张菁，教授，主要研究方向为抗菌药物临床药理学研究。

摘要：受助于美国FDA 优先审评资格，美国制药公司The Medicines Company 的Vabomere 注射剂（美罗培南+Vaborbactam ）进入临床开发不到8年时间，就于2017年8月29日，被批准用于成人复杂性尿路感染（complicated urinary tract infections, cUTI ）的治疗，为严重细菌感染患者提供了一种额外的治疗方案。

为方便国内学者了解Vabomere 的特性，特对其说明书进行翻译，包括适应证、用法用量、不良反应、药物相互作用、药理毒理、微生物学和临床研究等。

关键词：Vabomere ；复杂性尿路感染；不良反应；药理毒理；微生物学；临床研究中图分类号：R978.1 文献标识码：A 文章编号：1001-8751（2019）02-0106-092017年8月29H ,美国食品和药品监督管理局批准了美国制药公司The Medicines Company 的Vabomere 注射剂1（美罗培南+Vaborbactam ）用于成人复杂性尿路感染的治疗，Vabomere 是由合成的青霉烯类抗菌药物美罗培南和一种环硼酸卩-内酰胺酶抑制剂Vaborbactam 组合成的产品，用于静脉给药。

为方便国内学者了解Vabomere 的特性，特对其说明书进行翻译。

1适应证及用途Vabomere 适用于下列敏感菌引起的18岁及以上患者复杂性尿路感染，包括肾盂肾炎：大肠埃希菌、肺炎克雷伯菌和阴沟肠杆菌。

血管外膜细胞钙化及其钙化机制研究

血管外膜细胞钙化及其钙化机制研究谭小青,张旭升,樊小容,黄战军摘要目的:研究经体外诱导钙化建立大鼠血管外膜细胞钙化模型,检测钙化过程中成骨相关指标及凋亡㊁自噬相关蛋白的表达变化,旨在为心血管疾病模型提供更精确的细胞模型,并初步探讨其钙化机制㊂方法:原代提取大鼠胸主动脉外膜纤维细胞,取3~6代细胞使用诱导培养基(高糖DMEM +10%胎牛血清+10mmol/L β-甘油磷酸+0.05mmol/L 抗坏血酸+100mmol/L 地塞米松)诱导钙化,诱导时间为3d ㊁6d ㊁9d ㊁12d ㊁15d ,筛选出诱导细胞钙化的最佳时间㊂对细胞采用茜素红S 染色㊁细胞内钙含量测定和碱性磷酸酶(ALP )活性检测,鉴定是否成功构建钙化模型㊂采用实时定量聚合酶链式反应(PT -PCR )检测成骨相关因子骨形态生成蛋白2(BMP2)和核心结合因子α1(Runx2)的mRNA 含量,蛋白免疫印迹法(Western Blot )检测凋亡蛋白Bax ㊁Bcl -2和自噬相关蛋白微血管相关蛋白(LC3)㊁Beclin -1的表达水平,找出血管外膜细胞钙化的潜在机制㊂结果:当诱导钙化时间为15d 时,血管外膜细胞中主要钙化指标胞内钙含量及ALP 活性上调(P <0.05),茜素红S 染色显示钙化组有明显钙盐沉积㊂血管外膜细胞经钙化诱导后,BMP2和Runx2的mRNA 水平上调,Bax 蛋白水平上调,Bcl -2和Beclin -1蛋白水平下调,LC3-Ⅱ/LC3-Ⅰ比值上调(P <0.05)㊂结论:钙化诱导培养基培养血管外膜细胞15d 可成功构建钙化细胞模型,血管外膜细胞钙化可能与细胞向成骨样表型转化有关,血管外膜细胞钙化过程涉及细胞自噬及凋亡调控㊂关键词血管外膜细胞;钙化;成骨样表型转化;自噬与凋亡;实验研究d o i :10.12102/j.i s s n .1672-1349.2023.18.010 Calcification of Vascular Adventitial Cells and Its MechanismTAN Xiaoqing,ZHANG Xusheng,FAN Xiaorong,HUANG Zhanjun Longgang District People 's Hospital of Shenzhen,Shenzhen 518172,Guangdong,China Corresponding Author ZHANG Xusheng,E -mail:*****************Abstract Objective:To investigate the mananism of calcification of rat vascular adventitial cells,establish the calcification model of rat vascular adventitial cells,and detect the expression changes of osteogenesis -related indicators,apoptosis,and autophagy -related proteins during the calcification process.It aimed to provide more accurate cell models for cardiovascular disease and initially explore the mechanism of calcification.Methods:Rat thoracic aortic adventitial fibroblasts were extracted from the primary generation,and the 3rd to 6th generation cells were used for induction medium(high glucose DMEM +10%fetal bovine serum +10mmol/L β-glycerophosphate +0.05mmol/L ascorbic acid +100mmol/L dexamethasone)to induce calcification,the induction time was 3,6,9,12,and 15d,and the optimal time for inducing cell calcification was selected.The cells were stained with alizarin red S,detected by intracellular calcium content and alkaline phosphatase(ALP)to identify whether the calcification model was successfully constructed.Real -time quantitative reverse transcription polymerase chain reaction(RT -PCR)was used to detect the mRNA levels of osteogenesis -related factors bone morphogenetic protein(BMP2)and runt -related transcription factor 2(Runx2);Western Blot was used to detect the apoptosis proteins Bax,Bcl -2,the autophagy -related proteins LC -3,and Beclin -1expression level;then the potential mechanism of vascular adventitial cell calcification would be revealed.Results:When calcification was induced for 15days,the intracellular calcium content in the adventitial cells of the main calcification indicators and ALP activity were up -regulated(P <0.05).Alizarin red S staining showed obvious calcium deposits in the calcification group.After calcification was induced in adventitial cells,the mRNA levels of BMP2and Runx2up -regulated,the protein levels of Bax up -regulated,the protein levels of Bcl -2and Beclin -1down -regulated,and the ratio of LC3-Ⅱ/LC3-Ⅰdown -regulated(P <0.05).Conclusion:Adventitial cells cultured in the calcification -inducing medium for 15days could successfully construct a calcified cell model.calcification of adventitial cells might be related to the transformation of cells to an osteoblast -like phenotype.The Calcification process of adventitial cells involved autophagy and apoptosis regulation.Keywords adventitial cells;calcification;osteogenic phenotype transformation;autophagy and apoptosis;experimental study血管钙化常见于动脉粥样硬化㊁血脂异常㊁高血压㊁糖尿病㊁慢性肾病及衰老等人群[1],血管钙化引起血管硬度增加㊁顺应性降低,导致心肌缺血㊁心力衰竭㊁血栓形成等,增加脑卒中㊁心脏病㊁动脉粥样硬化斑块破裂等的风险,被认为是影响心血管疾病的重要因素之一[2-4]㊂目前关于血管内膜㊁中膜和心脏瓣膜钙化的关注和研究相对较多㊂临床工作中发现,血管外膜也可发生钙化,然而调查发现,现阶段对血管外膜钙化的作者单位深圳市龙岗区人民医院(广东深圳518172)通讯作者张旭升,E -mail :*****************引用信息谭小青,张旭升,樊小容,等.血管外膜细胞钙化及其钙化机制研究[J ].中西医结合心脑血管病杂志,2023,21(18):3347-3350.关注较少,因此,需要更多的研究来阐明血管钙化的致病机制㊂最初血管钙化被认为是被动和退行性病变,标志着血管老化,但是越来越多研究表明血管钙化是类似于胚胎骨形成的病理生物学过程[5-6]㊂Bostr öm 等[7-8]研究发现,钙化过程中大鼠血管中膜细胞由原有收缩表型转变成为成骨样细胞表型,原有的收缩标志物如平滑肌肌动蛋白α(α-SMA )等表达减少,并表达核心结合因子α1(Runx2)㊁骨形态生成蛋白2(BMP2)等多种成骨样标志物,从而介导骨基质在血管中沉积㊂细胞凋亡与自噬为2种细胞死亡的方式,与血管钙化息息相关,研究表明,血管中膜细胞在细胞凋亡过程中释放凋亡小体,促进细胞钙化,而细胞自噬通过多种机制调控细胞钙化[9-10]㊂本研究对大鼠血管外膜细胞进行体外诱导钙化,建立大鼠血管外膜细胞钙化模型,并检测钙化过程中成骨相关指标及凋亡㊁自噬相关蛋白的表达变化,旨在为心血管疾病模型提供更精确的细胞模型,并初步探讨其钙化机制㊂1材料与方法1.1试剂胎牛血清(FBS,Gibco),青霉素,链霉素(Gibco,美国),茜素红S溶液,β-甘油磷酸,抗坏血酸,地塞米松(Sigma,美国),抗GAPDH抗体(Bioworld),抗Bcl-2, Bax,Bcelin1和微血管相关蛋白(LC3)抗体(CST),碱性磷酸酶检测试剂盒㊁钙(Ca)检测试剂盒(南京建城生物工程研究所)㊂1.2大鼠血管外膜细胞分离与培养取10只4~6周龄雄性Wistar-Kyoto大鼠(体质量120~180g)胸主动脉分离血管外膜,采用组织黏附法培养㊂使用添加10%胎牛血清的高糖DMEM培养基(Gibco dmem)在37ħ㊁5%二氧化碳条件下培养细胞㊂当细胞增殖至80%~90%融合时,用0.25%胰酶消化传代㊂使用第3代至第6代的细胞进行后续实验㊂1.3体外钙化模型的建立钙化诱导培养基为含10%胎牛血清,10mmol/L β-甘油磷酸钠,0.05mmol/L抗坏血酸和100mmol/L 地塞米松的高糖DMEM培养液㊂将第3代至第6代细胞分为对照组和钙化组,待细胞长至50%融合时,使用钙化诱导培养基培养,每3d更换1次培养基,连续培养15d㊂1.4碱性磷酸酶(ALP)酶活测定细胞钙化诱导后,弃去培养基,1ˑ磷酸缓冲盐溶液(PBS)洗细胞3次,加入裂解液500μL(1%T ritonX-100),冰上裂解40min后,离心,取上清液㊂使用上清液根据试剂盒说明书检测ALP活性及总蛋白含量㊂1.5细胞内钙含量检测细胞钙化诱导后,弃去培养基,1ˑPBS洗细胞3次,每孔加入500μL0.6mol/L的盐酸4ħ脱钙过夜,取上清,根据钙测试试剂盒说明书检测钙含量㊂将脱钙后的细胞用4ħPBS洗3次,每孔加入500μL NaOH/0.1%SDS裂解细胞,取上清,用二喹啉甲酸法(BCA)测定细胞蛋白含量㊂1.6茜素红S染色细胞钙化诱导15d,弃去培养基,1ˑPBS洗细胞3次,加入0.5mL4%多聚甲醛室温固定15min,用双蒸水洗3次,加入1mL0.1%茜素红室温孵育15min,吸去染液,双蒸水洗3次,在倒置显微镜下观察㊂1.7实时定量聚合酶链式反应(RT-PCR)检测细胞钙化诱导后,弃去培养基,1ˑPBS洗细胞3次,使用TaKaRa MiniBEST Universal RNA Extraction Kit提取总RNA,使用PrimeScrip TM RT reagent Kit将所提取的RNA逆转录合成cDNA,以cDNA为模板,通过SYBR Green I嵌合荧光定量RT-PCR检测BMP-2㊁Runx2和GAPDH的表达量㊂引物序列见表1㊂表1引物序列基因方向序列Runx2正向5'-TGGCTTTGGTTTCAGGTTAGG-3'反向5'-TGGAGATGTTGCTCTGTTCG-3' BMP-2正向5'-TGAGGATTAGCAGGTCTTTGC-3'反向5'-TCTCGTTTGTGGAGTGGATG-3' GAPDH正向5'-GGCTGCCCAGAACATCAT-3'反向5'-CGGACACATTGGGGGTAG-3'1.8蛋白免疫印迹法(Western Blot)检测细胞钙化诱导15d,弃去培养基,1ˑPBS洗细胞3次,提取细胞总蛋白㊂使用12%SDS-PAGE胶电泳分离,并转移到聚偏二氟乙烯膜(PVDF)上,封闭后,加入一抗(Bax1ʒ1000,Bcl-21ʒ1000,Beclin11ʒ1000, LC31ʒ1000,GAPDH1:1000)稀释液,4ħ孵育过夜;加入二抗稀释液(1ʒ10000)室温孵育1h后,使用ECL发光试剂盒显影并计算灰度值㊂1.9统计学处理应用SPSS19.0软件进行统计处理,符合正态分布的定量资料以均数ʃ标准差(xʃs)表示,比较采用t检验,以P<0.05为差异有统计学意义㊂2结果2.1大鼠血管外膜细胞可在体外被诱导钙化为验证高磷是否能诱导大鼠血管外膜细胞钙化,使用钙化诱导培养基培养细胞,在不同时间点检测ALP活性和胞内钙含量㊂随着培养时间延长,ALP活性逐渐上升,在培养第12天达到峰值,与对照组比较差异有统计学意义(P<0.05);诱导第3天开始所测得的胞内钙含量与对照组比较升高(P<0.05),ALP 活性和钙含量升高具有时间依赖性㊂详见图1㊁图2㊂诱导15d所测得钙含量最高,因此,后续实验选择的诱导时间为15d㊂对钙化诱导15d的细胞进行茜素红S染色,结果显示,对照组细胞呈长梭形,而钙化组细胞变成菱形㊂茜素红S染色后,钙化组可观察到大量的橘红色钙结节(见图3),而对照组完全没有㊂这也证明大鼠血管外膜细胞可在体外被钙化培养基诱导钙化㊂图1钙化诱导培养基诱导外膜细胞后ALP含量(与0d时比较,*P<0.05)图2钙化诱导培养基诱导外膜细胞后胞内钙含量(与0d时比较,*P<0.05)图3培养15d时细胞经茜素S红染色切片图(ˑ100)2.2血管外膜细胞钙化与细胞向成骨样表型转化有关血管钙化的增加与成骨细胞特异性标志物如BMP2㊁和Runx2的增加有关[11]㊂RT-PCR结果显示,与对照组比较,钙化组的成骨细胞特异性标志物BMP2和Runx2mRNA表达量增加,与对照组比较差异有统计学意义(P<0.05)㊂详见图4㊂图4外膜细胞钙化过程中BMP2和Runx2mRNA表达量(与对照组比较,*P<0.05)2.3血管外膜细胞钙化过程涉及细胞自噬及凋亡调控通过Western Blot检测凋亡和自噬相关蛋白的表达量变化㊂与对照组比较,钙化组促凋亡蛋白Bax表达上调,抑凋亡蛋白Bcl-2表达下调(P<0.05)㊂详见图5㊂钙化组自噬相关蛋白Beclin1表达上调,LC3-Ⅱ/ LC3-Ⅰ比例上调(P<0.05),说明钙化诱导培养后细胞内凋亡水平上调㊁自噬水平升高㊂详见图6㊂图5诱导钙化后促凋亡蛋白及抑凋亡蛋白表达变化图6诱导钙化后凋亡及自噬蛋白Beclin1等表达变化3讨论血管钙化作为心血管疾病病人的并发症之一,其发病率与严重程度逐年增高及加重,是导致心血管疾病病人高死亡率的重要因素㊂血管钙化缺乏有效的治疗药物㊂因此,探究血管钙化发病机制,在分子水平寻找有效的诊断和防治靶点是急需开展的基础研究工作㊂本研究证明,使用10mmol/Lβ-甘油磷酸+0.05 mmol/L抗坏血酸+100mmol/L地塞米松培养外膜细胞即可诱导大鼠血管外膜细胞在体外发生钙化,这是通过茜素红S染色㊁ALP活性检测及胞内钙含量检测结果得以确定的㊂血管钙化过程中,血管中膜细胞向成骨样细胞表型转变并表达相关成骨标志物,从而引起骨基质的沉积,是血管钙化的重要特点及机制[5]㊂本实验所用的血管外膜细胞钙化条件与血管中膜细胞钙化条件一致,说明血管外膜细胞钙化的机制可能与中膜细胞钙化的机制部分一致㊂血管中膜细胞钙化过程中,细胞表达成骨相关的转录因子如Runx2等,进而促进下游表达骨相关蛋白如骨形态发生蛋白BMP2等的表达,从而促使细胞向成骨样细胞主动分化[12-13],本研究也观察到类似的机制㊂通过PT-PCR检测,发现钙化培养基培养大鼠血管外膜细胞15d后,BMP2和Runx2的mRNA表达水平升高㊂本研究通过对钙盐沉积与成骨样细胞表型转变2个维度的探讨,证明血管外膜细胞可在体外被诱导钙化,丰富了血管钙化的分型㊂血管钙化的发生机制复杂,涉及多种信号通路,如细胞自噬和凋亡㊁Wnt/β-catenin信号通路激活㊁内质网应激等均参与调控血管钙化的过程㊂自噬作为一种细胞应激的适应性反应,在维持血管结构与功能中十分关键㊂研究表明,血管钙化过程中自噬水平增高[14-15]㊂在体外实验中,高磷可提高大鼠血管中膜细胞的自噬水平,增加细胞内自噬体数量,从而抑制凋亡与钙化[16]㊂还有研究表明,自噬可通过抑制大鼠血管中膜细胞氧化应激,抑制血管内皮细胞的炎症反应,对三酰甘油等脂代谢进行调控,从而减轻血管钙化[17-18]㊂LC3和Beclin1是2种典型的自噬标志物,Western Blot实验结果表明,用钙化培养基诱导大鼠血管外膜细胞15d,LC3-Ⅱ/LC3-Ⅰ比率升高,Beclin1蛋白水平表达升高,说明细胞内自噬水平升高㊂多项研究表明,细胞凋亡参与促进血管钙化的发生,抑制细胞凋亡和抑制钙化[16-17]㊂在对大鼠的体内研究发现,成纤维细胞生长因子21通过内质网应激调控Caspase-12信号通路来减少血管内中膜细胞凋亡,从而抑制血管钙化[18]㊂另外,提高培养基中的Pi 或Ca2+浓度,可诱导细胞质膜形成并释放基质囊泡(如凋亡小体),从而导致细胞外基质钙化,这种基质钙化可能成为血管钙化的成核位点[19]㊂Bax和Bcl-2是2种典型的凋亡和抑制凋亡蛋白,本实验结果证明,利用钙化培养基对血管外膜细胞诱导钙化过程中,细胞内凋亡水平升高㊂同时细胞内自噬水平也升高,这可能是细胞自我调控以对抗钙化的结果㊂本研究证实血管外膜细胞可在体外被诱导钙化,且外膜钙化过程与骨组织钙化过程类似,为主动可调控的过程㊂血管钙化是一个复杂的过程,涉及细胞凋亡和自噬等调控通路,仍需进一步研究㊂参考文献:[1]梁英权,段亚君,韩际宏.血管钙化分子机制研究进展[J].中国动脉硬化杂志,2020,28(11):921-929.[2]NICOLL R,HENEIN M Y.The predictive value of arterial andvalvular calcification for mortality and cardiovascular events[J].Int J Cardiol Heart Vessel,2014,3:1-5.[3]JOHNSON R C,LEOPOLD J A,LOSCALZO J.Vascularcalcification:pathobiological mechanisms and clinical implications[J].Circulation Research,2006,99(10):1044-1059.[4]YAMADA S,GIACHELLI C M.Vascular calcification in CKD-MBD:roles for phosphate,FGF23,and Klotho[J].Bone,2017,100:87-93.[5]LIN M E,CHEN T M,WALLINGFORD M C,et al.Runx2deletion insmooth muscle cells inhibits vascular osteochondrogenesis andcalcification but not atherosclerotic lesion formation[J].Cardiovascular Research,2016,112(2):606-616.[6]DURHAM A L,SPEER M Y,SCATENA M,et al.Role of smoothmuscle cells in vascular calcification:implications in atherosclerosis andarterial stiffness[J].Cardiovascular Research,2018,114(4):590-600.[7]BOSTRÖM K I,RAJAMANNAN N M,TOWLER D A.The regulationof valvular and vascular sclerosis by osteogenic morphogens[J].Circulation Research,2011,109(5):564-577.[8]SPEER M Y,YANG H Y,BRABB T,et al.Smooth muscle cells giverise to osteochondrogenic precursors and chondrocytes incalcifying arteries[J].Circulation Research,2009,104(6):733-741.[9]PROUDFOOT D,SKEPPER J N,HEGYI L,et al.Apoptosisregulates human vascular calcification in vitro:evidence forinitiation of vascular calcification by apoptotic bodies[J].Circulation Research,2000,87(11):1055-1062.[10]AN S J,BOYD R,ZHU M,et al.NADPH oxidase mediatesangiotensin II-induced endothelin-1expression in vascularadventitial fibroblasts[J].Cardiovascular Research,2007,75(4):702-709.[11]ZEADIN M,BUTCHER M,WERSTUCK G,et al.Effect of leptin onvascular calcification in apolipoprotein E-deficient mice[J].Arterioscler Thromb Vasc Biol,2009,29(12):2069-2075. [12]LEOPOLD J A.Vascular calcification:mechanisms of vascularsmooth muscle cell calcification[J].Trends in CardiovascularMedicine,2015,25(4):267-274.[13]刘聿秀.高尿酸诱导血管钙化的机制研究[D].青岛:青岛大学,2015.[14]LIU Q,LUO Y,ZHAO Y,et al.Nano-hydroxyapatite acceleratesvascular calcification via lysosome impairment and autophagydysfunction in smooth muscle cells[J].Bioact Mater,2022,8:478-493.[15]LIANG J,HUANG J,HE W,et al.β-Hydroxybutyric Inhibits vascularcalcification via autophagy enhancement in models induced byhigh phosphate[J].Front Cardiovasc Med,2021,8:685748. [16]CICERI P,ELLI F,CAPPELLETTI L,et al.A new in vitro model todelay high phosphate-induced vascular calcification progression[J].Mol Cell Biochem,2015,410(1/2):197-206.[17]BYON C H,JAVED A,DAI Q,et al.Oxidative stress inducesvascular calcification through modulation of the osteogenictranscription factor Runx2by AKT signaling[J].The Journal ofBiological Chemistry,2008,283(22):15319-15327.[18]OUIMET M,FRANKLIN V,MAK E,et al.Autophagy regulatescholesterol efflux from macrophage foam cells via lysosomal acidlipase[J].Cell Metabolism,2011,13(6):655-667.[19]REYNOLDS J L,JOANNIDES A J,SKEPPER J N,et al.Humanvascular smooth muscle cells undergo vesicle-mediatedcalcification in response to changes in extracellular calcium andphosphate concentrations:a potential mechanism for acceleratedvascular calcification in ESRD[J].Journal of the AmericanSociety of Nephrology,2004,15(11):2857-2867.(收稿日期:2022-03-30)(本文编辑王雅洁)。

培美曲塞二钠杂质列表-杂质对照品

培美曲塞二钠杂质列表-杂质对照品序号杂质名称或编号英文名CAS结构式及CAS
1培美曲塞二钠杂
质A Pemetrexed EP
Impurity A
869791-42-4
2培美曲塞二钠杂
质D Pemetrexed EP Impurity D
3培美曲塞二钠杂
质E Pemetrexed EP Impurity E
相关杂质1、阿考替胺杂质2、维格列汀杂质3、厄洛替尼杂质4、利伐沙班杂质5、索拉非尼杂质
6、阿伐那非杂质
7、替卡格雷杂质
8、阿哌沙班杂质
9、米格列奈杂质10、普拉克索杂质11、氨氯地平杂质12、非不司他杂质13、托法替尼杂质14、达比加群酯杂质15、埃索美拉唑钠杂质16、盐酸氨溴索杂质 17、卡格列净杂质 18 索菲布韦杂质 19、依托考昔杂质
及代理其他品牌杂质标准品（EP、USP、LGC、TRC、TLC、MC、SINCO）等。

联系电话：0755 - 89483656
深圳菲斯—专注标准品。

细胞蛇的研究进展

2007年,英国牛津大学的刘骥陇等在研究果蝇U 小体和P 小体(U 小体和P 小体是真核生物细胞质中的无膜细胞器)的功能关系时,用4种针对Cup (P 小体中的一种蛋白质)的抗体,对雌性果蝇的卵巢组织进行免疫组织化学染色,染色结果除了预期标记上的P 小体外,还标记出了长条形的丝状结构[1]。

这种结构的形状和数量与纤毛很相似,导致当时以为在果蝇中找到了有纤毛的新细胞类型。

但后来的一系列实验表明,该结构与纤毛没有关系,于是将其命名为“细胞蛇”。

最初是抗Cup 抗体不纯产生假象,意外发现的细胞蛇,而采用亲和层析纯化后的抗Cup 抗体无法再DOI:10.16605/ki.1007-7847.2020.10.0258细胞蛇的研究进展收稿日期:2020-10-22;修回日期:2020-11-19;网络首发日期:2021-07-27基金项目:宁夏自然科学基金项目(2020AAC03179);国家自然科学基金资助项目(31560329)作者简介:李欣玲(1999—),女,广西贵港人,学生;*通信作者:俞晓丽(1984—),女,宁夏银川人,博士,副教授,主要从事干细胞与生殖生物学研究,E-mail:********************。

李欣玲,张樱馨,李进兰,潘文鑫,王彦凤,杨丽蓉,王通,俞晓丽*(宁夏医科大学生育力保持教育部重点实验室临床医学院基础医学院,中国宁夏银川750000)摘要:细胞蛇是近年来细胞生物学研究的热门方向之一,由于其在细胞的增殖、代谢和发育上具有一定的生物学功能,因此,对一些疾病如癌症等的临床诊断或治疗具有一定的指导意义。

细胞蛇是由三磷酸胞苷合成酶(cytidine triphosphate synthetase,CTPS)聚合而成的无膜细胞器,其形成过程及功能在不同类型的细胞中不尽相同。

例如:细胞蛇能促进癌细胞增殖,并使患者病情恶化;过表达的细胞蛇可抑制神经干细胞增殖,影响大脑皮层发育;在卵泡细胞中,细胞蛇相当于CTPS 的存储库,在卵子发生过程起到促进细胞增殖和代谢的作用。

F-STOP 对照图片，病毒免疫咖啡草坛说明书

F -S T O P ™ F o r P i c t u r e -P e r f e c t , D i s e a s e -F r e e T u r f g r a s s 12770• Provides Systemic Prevention And Control Of Turfgrass Diseases• Prevents Over 15 Major Lawn Diseases • For Use On All Types Of Home Lawns • One Application Protects For Up To 4 WeeksKEEP OUT OF REACH OF CHILDRENCAUTIONBUYER ASSUMES ALL RISKS OF USE, STORAGE OR HANDLING OF THIS MATERIALNOT IN STRICT ACCORDANCE WITH DIRECTIONS GIVEN HEREWITH.NET WEIGHT 10 LBS. (4.53 KG)ACTIVE INGREDIENT:myclobutanil: a-butyl-a-(4-chlorophenyl)-1-H-1,2,4 triazole-propanenitrile: ...............0.39%OTHER INGREDIENTS: .............................................................................................99.61%TOTAL .....................................................................................................................100.00%This product contains 0.195 lb.. of myclobutanil per 50 lb. bag.C o v e r s U p T o 2,500 S q . F t .F-STOP ™ For Picture-Perfect, Disease-Free TurfgrassF -S T O P ™F o r P i c t u r e -P e r f e c t , D i s e a s e -F r e e T u r f g r a s sF-STOP ™For Picture-Perfect, Disease-Free TurfgrassPRECAUTIONARY STATEMENTSHAZARDS TO HUMANS AND DOMESTIC ANIMALSCauses Moderate Eye Irritation.Avoid contact with eyes or clothing. Wash thoroughly with soap and water after handling and before eating, drinking, chewing gum, using tobacco, or using the toilet.Notice: Read the entire label. Use only according to label directions. Before using this product, read “Warranty Disclaimer,” “Inherent Risks of Use,” and “Limitation of Remedies” at end of Directions for Use. If terms are unacceptable, return at once unopened.In case of emergency endangering health or the environment involving this product,call 1-800-992-5994Agricultural Chemical: Do not ship or store with food, feeds, drugs, or clothing.FIRST AIDIf in eyes: Hold eye open and rinse slowly and gently with water for 15-20 minutes. Remove contact lenses, if present, after the ﬁrst 5 minutes, then continue rinsing eye. Call a Poison Control Center or doctor for treatment advice. Have the product container or label with you when calling a Poison Control Center or doctor, or going for treatment. You may also contact 1-800-992-5994 for emergency treatment information.ENVIRONMENTAL HAZARDSThis pesticide is toxic to ﬁsh. To protect the environment, do not allow pesticide to enter or run off into storm drains, drainage ditches, gutters or surface waters. Applying this product in calm weather when rain is not predicted for the next 24 hours will help ensure that wind or rain does not blow or wash pesticide off the treatment area. Sweeping any product that lands on a driveway, sidewalk, or street, back onto the treated area of the lawn or garden will help to prevent runoff to water bodies or drainage systems.DIRECTIONS FOR USEIt is a violation of Federal law to use this product in a manner inconsistent with its labeling. Read all directions carefully before applying this product.Not for use on turfgrass being grown for sale or other commercial use as sod, or for commercial seed productions, or for research purposes.STORAGE AND DISPOSALDo not contaminate water, food or feed by storage and disposal.PESTICIDE STORAGE: Keep away from ﬁre and sparks. Store in a cool, dry, well-ventilated area. CONTAINER HANDLING: Nonreﬁllable container. Do not reuse or reﬁll this container.If empty: Place in trash or offer for recycling if available.If partly ﬁlled: Call your local solid waste agency for disposal instructions. Never place unused product down any indoor or outdoor drain.HOW THIS PRODUCT WORKSferti•lome® F-STOP™is a systemic, protectant and curative fungicide for the control of listed diseases in established home lawns and ornamental turfgrass. Optimum disease control is achieved when this product is applied to established turfgrass in a regularly scheduled preventative program. Use this product in conjunction with turf management practices that promote good plant health and optimum disease control. The key to selecting a fungicide is the proper diagnosis of the organism causing the disease. Diagnostic kits, extension experts, or other identiﬁcation methods should be used when developing disease control strategies.HOW TO APPLYApply ferti•lome® F-STOP™ uniformly over the turfgrass area using a properly calibrated drop or rotary-type spreader designed to apply granules. Before each application, calibrate the spreader according to the equipment manufacturer’s directions. Check frequently to make sure equipment is operating properly and distributing product uniformly. A more uniform application may be achieved by spreading half of the required amount of product over the area and then applying the remaining half in swaths at a right angle to the ﬁrst. Avoid skips and excessive overlaps during application. Avoid the use of spreaders that apply this product in narrow rows or concentrated bands.Wash hands with soap and water promptly after use.Do not allow people or pets to contact treated area until after product dust has settled into the turfgrass, or if watered in, after the turfgrass surface in the treated area has dried.WHEN TO APPLYReduce the interval between applications of this product when conditions are favorable for disease development. Unless otherwise speciﬁed, when disease pressure is high or when used as a curative, use higher rates of ferti•lome® F-STOP™ and shorter application interval. Under light to moderate disease pressure apply this product at the low use rate and/or longer application intervals. To avoid pick-up, lightly irrigate treated areas soon after application. On short cut bentgrass (1/2 inch or less) when temperatures are above 80°F, apply only to dry foliage.HOW MUCH TO APPLYOptimum disease control is achieved when ferti•lome® F-STOP™ is applied in a preventative disease control program at a rate of 4 lb per 1,000 sq. ft. See the following table for speciﬁc application rates for various diseases. Under any circumstances, do not apply more than 46 lb of this product per1,000 sq. ft. per year.SPREADER GUIDEONE BAG WILL COVER UP TO 2,500 SQUARE FEETSPREADER SPREADER SETTINGS Scotts®/Republic Accugreen (Drop) 4 1/4Scotts®/Republic Speedy Green (Broadcast) 3 3/4 ferti•lome® /EarthWay Ev-N-Spred (Broadcast)14TERMS AND CONDITION OF USEIf terms of the following Warranty Disclaimer, Inherent Risks of Use, and Limitation of Remedies are not acceptable, return unopened package at once to the Seller for a full refund of purchase price paid. Otherwise, use by the Buyer or any other user constitutes acceptance of the terms under Warranty Disclaimer, Inherent Risks of Use, and Limitations of Remedies.WARRANTY DISCLAIMERSeller warrants that this product conforms to the chemical description of the label and is reasonably ﬁt for the purposes stated on the label when used in strict accordance with the directions, subjectto the Inherent Risks set forth below. Seller MAKES NO OTHER EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER EXPRESS OR IMPLIED WARRANTY.INHERENT RISKS OF USEIt is impossible to eliminate all risks associated with use of this product. Plant injury, lack of performance, or other unintended consequences may result because of such factors as use of the product contrary to label instructions (including conditions noted on the label, such as unfavorable temperature, soil conditions, etc.), abnormal conditions (such as excessive rainfall, drought, tornadoes, hurricanes), presence of other materials, the manner of application, or other factors, allof which are beyond the control of the Seller. To the extent allowed by law, all such risks shall be assumed by the Buyer.LIMITATION OF REMEDIESTo the extent consistent with applicable law, the exclusive remedy for losses or damages resulting from this product (including claims based on contract, negligence, strict liability, or other legal theories), shall be limited to, at Seller’s election, one of the following:1. Refund of purchase price paid by Buyer or user for product bought, or2. Replacement of amount of product used.To the extent allowed by law, Seller shall not be liable for the losses of damages resulting from the handling or use of this product unless Seller is promptly notiﬁed of such loss or damage in writing. In no case shall Seller be liable for consequential or incidental damages or losses.The terms of the Warranty Disclaimer and Inherent Risks of Use above and this Limitation of Remedies cannot be varied by any written or verbal statements or agreements. No employee or sales agent of Seller or the Seller is authorized to vary or exceed the terms of the Warranty Disclaimer or this Limitation of Remedies in any manner.Disease ferti•lome® F-STOP™(lb/1,000 sq ft)ApplicationInterval/Timing(Days)Directions RestrictionsAnthracnose Red Thread Septoria Leaf Spot 414 - 21Apply when conditions are favorable for disease development.Do not apply more than 46pounds of product per 1,000sq. ft. per year.For Nassau and Suffolkcounties in New York State,do not apply more than 11.5lb of this product per 1,000sq ft per year.Brown Patch14Begin applications when conditions are favorable for disease development andb efore disease symptoms are apparentCopper SpotZonate Leaf SpotApply when conditions are favorable for disease development.Crown Rot Leaf Spot Melting-Out Apply when conditions are favorable for disease development. For crown rot, water in with 3 to 4 gallons of water per 1,000 sq. ft. to increase penetration to crown a nd roots.Dollar Spot14 - 28Apply when conditions are favorable for disease development. Make no morethan 3 consecutive applications for Dollar Spot control before rotating to aregistered fungicide with a diiferent mode of actionFusarium Blight14 - 21Apply when conditions are favorable for disease development.Fusarium Patch(Pink Snow Mold)21 - 28Apply when conditions are favorable for disease development.Gray Leafspot14Apply prior to snow cover.Leaf Spot Apply in the fall after turfgrass enters dormancy and/or in the spring prior to theinitiation of growth.Necrotic Ring Spot Spring: 28Make applications on a preventative basis in early to mid-spring.Necrotic Ring Spot Fall: 28Make 2 applications beginning in August before the turfgrass goes dormant.Powdery MildewRusts14 - 28Apply when conditions are favorable for disease development.Summer Patch Begin applications in the spring when conditions are favorable for disease de-velopment. Make 2 to 4 applications depending on recommendations from localTurfgrass Extension Experts.Water in with at least 3 to 4 gallons of water per 1,000 sq. ft. to increase penetra-tion to crown and roots.Manufactured by:230 FM 87 • BONHAM, TEXAS 75418EPA Reg. No. 62719-461-7401 EPA Est. No. 7401-TX-01Visit Us At: Product Questions? 855-270-477612770-0515-TP。

Alda-1_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Alda–1 is a potent ALDH2 agonist, which significantly improves ALDH2 activity.In Vivo: Alda–1 treatment results in a significant decrease of 4–HNE–protein content in the plasma of apoE -/- mice. Alda–1administration leads to a slight increase in gene expression related to neurogenesis (Nog ), mitochondrial biogenesis (CYTB , ND1),and apoptosis (Bax , Gsk3b ) in the Hp of apoE -/- mice. Alda–1 administration leads to 2 and 10 differentially expressed proteins in theFCx and Hp of apoE -/- mice, respectively [1]. Alda–1 (1.5 mg/kg, b.w., i.p.) administration significantly increases the climbing time,tends to reduce the immobility time and increases the swimming time of the prenatally stressed rats in the forced swim test.Moreover, treatment of prenatally stressed rats with Alda–1 significantly increases number of entries into the open arms of the maze and the time spent therein, as assessed by elevated plus–maze test [2]. Alda–1 (8.5 mg/kg, i.p.) with glucose significantly lowers 4–HNE and FJB–positive cells in the cerebral cortex of Alda–1–treated rats than in DMSO–treated rats 24 h after glucose administration [3]. Alda–1 (10 mg/kg per day) treatment prevents aldehydic overload, mitochondrial dysfunction and improves ventricular function in post–MI cardiomyopathy rats [4].PROTOCOL (Extracted from published papers and Only for reference)Cell Assay:[2]Spleen cells (4×106 cells/mL) are stimulated by optimal concentrations of concanavalin A (Con A; 2.5μg/mL and 0.6 μg/mL) and lipopolysaccharide (LPS, 5 μg/mL) and are incubated in 96–well plates at final volume of 0.2mL for 72 h. Cell proliferation is determined by adding 0.5 μCi of [3H]–thymidine per well at 16 h before the end of the incubation.The cultures are harvested with an automatic cell harvester, and [3H] thymidine incorporation is assessed using a liquid scintillationcounter.Animal Administration: Alda–1 is dissolved in 1 mL/kg b.w. DMSO/water 50/50.[2]After behavioral verification at three months of age,the animals are divided into the following four groups: control, control + Alda–1, prenatally stressed and prenatally stressed + Alda–1(6 animals per group). Alda–1 injections are given intraperitoneally (i.p.) once daily at a dose of 1.5 mg/kg b.w. (dissolved in 1 mL/kg b.w. DMSO/water 50/50) for 14 days. At the same time, the control and prenatally stressed rats receive 1 mL/kg b.w. DMSO/water 50/50. The injections of Alda–1 and vehicle are given between 10 a.m and 11 a.m. In the last five days of Alda–1 treatment the behavioral parameters in the elevated plus maze test and then in the forced swim test are measured.References:[1]. Stachowicz A, et al. Proteomic Analysis of Mitochondria–Enriched Fraction Isolated from the Frontal Cortex and Hippocampus of Apolipoprotein E Knockout Mice Treated with Alda–1, an Activator of Mitochondrial Aldehyde Dehydrogenase (ALDH2). Int J Mol Sci.[2]. Stachowicz A, et al. The impact of mitochondrial aldehyde dehydrogenase (ALDH2) activation by Alda–1 on the behavioral and biochemical disturbances in animal model of depression. Brain Behav Immun. 2016 Jan;51:144–53.Product Name:Alda–1Cat. No.:HY-18936CAS No.:349438-38-6Molecular Formula:C 15H 11Cl 2NO 3Molecular Weight:324.16Target:Aldehyde Dehydrogenase (ALDH)Pathway:Metabolic Enzyme/Protease Solubility:DMSO: ≥ 51 mg/mL[3]. Ikeda T, et al. Effects of Alda–1, an Aldehyde Dehydrogenase–2 Agonist, on Hypoglycemic Neuronal Death. PLoS One. 2015 Jun 17;10(6):e0128844.[4]. Gomes KM, et al. Aldehydic load and aldehyde dehydrogenase 2 profile during the progression of post–myocardial infarction cardiomyopathy: benefits of Alda–1. Int J Cardiol. 2015 Jan 20;179:129–138.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

主要种子贸易国家番茄褐色皱果病毒植物检疫措施

８４２０２４ꎬ Ｖｏｌ４４ꎬ Ｎｏ０９
农业与技术 ※种植科学

２５日本检疫措施
日本农林水产省 ( ＭＡＦＦ) 对 « 植物保护法实施
※种植科学农业与技术２０２４ꎬ Ｖｏｌ４４ꎬ Ｎｏ０９８３
高度重视ꎬ 包括我国在内的欧盟、美国、日本、韩
认已知未发生番茄褐色皱果病毒的生产基地生产ꎬ 种
物风险分析框架» ( ＩＳＰＭ２) 、 « 检疫性有害生物风险
险分析» ( ＩＳＰＭ２１) ꎬ 针对性地开展进出境种子携带
有害生物的风险分析ꎬ 以及确定后续要采取的植物检
疫措施ꎮ 植物检疫措施可以施用于作物生长及种子生
产、加工过程中的各个时期ꎮ 各项植物检疫措施可以
２主要种子贸易国家和地区检疫措施
番茄褐色皱果病毒扩散迅速ꎬ 已经引起国际间的
收稿日期: ２０２４－０３－１８
基金项目: 海关总署２０２２年科研计划项目 ( 项目编号: ２０２２ＨＫ０１０) ꎻ 海关总署２０２１年科研计划项目 ( 项目编号: ２０２１ＨＫ１６６)
作者简介: 王建坤 (１９８３－) ꎬ 男ꎬ 硕士ꎬ 一级主管ꎮ 研究方向: 进出境植物检疫ꎻ 通讯作者付海滨ꎬ 博士ꎬ 研究员ꎮ
列、德国、土耳其、约旦、希腊、英国、巴勒斯坦、
意大利、西班牙、中国 ( 已根除) 等 [３ꎬ４] ꎮ
番茄褐色皱果病毒主要为害寄主植物的叶片、茎
秆、花萼和果实等部位ꎮ 病毒入侵后ꎬ 嫩叶、顶芽会
出现花叶的症状ꎻ 叶片会出现变窄、畸形的症状ꎻ 茎
秆和萼片会显露坏死条斑ꎻ 花萼早期会产生着色、褐
子抽样ꎬ 使用逆转录—聚合酶链反应方法或实时荧光

新鲜平皿培养基和一次性培养基系列.

100g 100g
100.00 315 ． 00
用于大肠埃希氏菌快速荧光测定（使用时需添加 MUG）
用于食品、饮料和饮用水中的大肠菌群快速检验和计数。灭菌冷却后加入过滤除菌的头孢磺啶 500ug/ml
M0040 M0041
250g 250g
60．00 105 ． 00
用于细菌硫化氢试验用于肠道菌增菌培养
250g 250g 250g 250g 100g 250g 250g 250g 250g 250g 100g 250g 250g 250g
78.00 54.00 48.00 51.00 70.00 90.00 68.00 68.00 54.00 70.00 80.00 11盐发酵培养基 Lactose Bile Broth 乳糖发酵管 Lactose Ferment Broth 蔗糖发酵培养基 Sucrose Feument Medium 营养肉汤（NB） Nutrient Broth Cary-Blair 运送培养基 Cary-Blair Transport Medium EC 肉汤 E．Coli Broth 双糖铁培养基（上层） Kligler Iron Medium （Up）双糖铁培养基（下层） Kligler Iron Medium（Under）葡萄糖发酵培养基 Dextrose Ferment Medium 中国蓝琼脂 China Blue Agar Honda 产毒肉汤基础 Honda Toxin-Producing Medium 山梨醇麦康凯琼脂 Sorbitol Maconkey Medium 品红亚硫酸钠培养基（滤膜法） Fuchsin Basic Sodium Sulfite Agar 品红亚硫酸钠培养基（多管发酵法） Fuchsin Basic Sodium Sulfite Agar 磷酸盐葡萄糖蛋白胨水 Buffer Peptone Glucose Med Phospnate Guicose Peptone Water 蛋白胨水 Tryptone Broth 半固体琼脂 Semi-Solid Agar 肉汤琼脂培养基 Broth Agar Med 平板菌落计数培养基础（PCA） Plate Coumt Agar 氰化钾培养基基础 Potassium Cyanide Medium Base 乳糖蛋白胨培养液 Lactose Peptone Broth 5%乳糖发酵管 5%Lactose Ferment Broth 乳糖胆盐培养基 Lactose Bile Medium 糖发酵基础 Glucide Fulfate Base 克氏枸椽酸盐培养基 Christensen Citrste Medium 苯丙氨酸培养基 Pheylaianine Deaminase Agar Medium

1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。

Inhibitors, Agonists, Screening Libraries
Data Sheet
BIOLOGICAL ACTIVITY:
Vaborbactam is a cyclic boronic acid pharmacophore β–lactamase inhibitor.
In Vitro: Vaborbactam is a broad spectrum of inhibition of β–lactamases, with particularly potent activity against KPC, CTX–M, SHV,and CMY enzymes [1]. Vaborbactam restores meropenem activity for 72.7 to 98.1% of CPE isolates at ≤2 μg/mL, and maximum potentiation is achieved with fixed concentrations of ≥8 μg/mL of the inhibitor (≥96.5% of isolates are inhibited at ≤2 μg/mL of meropenem–vaborbactam). Meropenem–vaborbactam with a fixed concentration of 8 μg/mL of the inhibitor (MIC50, ≤0.06 μg/mL for all organisms) inhibits 93.7% of the CPE isolates displaying elevated meropenem MICs at ≤1 μg/mL [2]. By forming a reversible dative bond with the blactamase, vaborbactam acts as a competitive inhibitor and is not hydrolyzed by the b–lactamase [3].In Vivo: Vaborbactam is well tolerated and has a half–life of 1.23 h, and steadystate volume of distribution of 21.0 L in subjects [3].References:
[1]. Hecker SJ, et al. Discovery of a Cyclic Boronic Acid β–Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. J Med Chem. 2015May 14;58(9):3682–92.
[2]. Castanheira M, et al. Effect of the β–Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase–Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5454–8.
[3]. Wong D, et al. Novel Beta–Lactamase Inhibitors: Unlocking Their Potential in Therapy.
Product Name:
Vaborbactam Cat. No.:
HY-19930CAS No.:
1360457-46-0Molecular Formula:
C 12H 16BNO 5S Molecular Weight:
297.14Target:
Bacterial Pathway:
Anti–infection Solubility:
DMSO: 10 mM
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

Vaborbactam_DataSheet_MedChemExpress

合集下载

安进—阿法达贝泊汀 PPT课件

分子生物学词汇(中英文对照表 )

2022最新帕拉米韦杂质列表汇总(现)

布地奈德与复方异丙托溴铵雾化吸入

工作场所空气中有毒物质容许浓度

Presatovir产品说明书

玛巴洛沙韦结构式

感控相关英语单词短语及缩写中英对照

爱利亚（阿培布塞普）商品说明书

Vabomere药品说明书

血管外膜细胞钙化及其钙化机制研究

培美曲塞二钠杂质列表-杂质对照品

细胞蛇的研究进展

F-STOP 对照图片，病毒免疫咖啡草坛说明书

Alda-1_DataSheet_MedChemExpress

主要种子贸易国家番茄褐色皱果病毒植物检疫措施

新鲜平皿培养基和一次性培养基系列.

文档推荐

最新文档

Vaborbactam_DataSheet_MedChemExpress

合集下载

安进—阿法达贝泊汀 PPT课件

分子生物学词汇(中英文对照表 )

2022最新帕拉米韦杂质列表汇总(现)

布地奈德与复方异丙托溴铵雾化吸入

工作场所空气中有毒物质容许浓度

Presatovir产品说明书

玛巴洛沙韦 结构式

感控相关英语单词短语及缩写中英对照

爱利亚（阿培布塞普）商品说明书

Vabomere药品说明书

血管外膜细胞钙化及其钙化机制研究

培美曲塞二钠杂质列表-杂质对照品

细胞蛇的研究进展

F-STOP 对照图片，病毒免疫咖啡草坛说明书

Alda-1_DataSheet_MedChemExpress

主要种子贸易国家番茄褐色皱果病毒植物检疫措施

新鲜平皿培养基和一次性培养基系列.

文档推荐

最新文档

玛巴洛沙韦结构式